Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, Smith JW 2nd, Richards PD, Gernhardt D, Huang X, Liau KF, Kern KA, Davis J. Robert NJ, et al. Among authors: minton se. Clin Breast Cancer. 2011 Apr;11(2):82-92. doi: 10.1016/j.clbc.2011.03.005. Epub 2011 Apr 11. Clin Breast Cancer. 2011. PMID: 21569994 Free PMC article. Clinical Trial.
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. Munster PN, et al. Among authors: minton se. Br J Cancer. 2011 Jun 7;104(12):1828-35. doi: 10.1038/bjc.2011.156. Epub 2011 May 10. Br J Cancer. 2011. PMID: 21559012 Free PMC article. Clinical Trial.
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. DeMichele A, et al. Among authors: minton se. Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24. Clin Cancer Res. 2015. PMID: 25712686 Free PMC article.
Male breast cancer: management and follow-up recommendations.
Kiluk JV, Lee MC, Park CK, Meade T, Minton S, Harris E, Kim J, Laronga C. Kiluk JV, et al. Breast J. 2011 Sep-Oct;17(5):503-9. doi: 10.1111/j.1524-4741.2011.01148.x. Epub 2011 Aug 29. Breast J. 2011. PMID: 21883641
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, Tolcher AW, Minton S. Molife LR, et al. J Hematol Oncol. 2014 Jan 3;7:1. doi: 10.1186/1756-8722-7-1. J Hematol Oncol. 2014. PMID: 24387695 Free PMC article. Clinical Trial.
38 results